Profile data is unavailable for this security.
About the company
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
- Revenue in USD (TTM)314.95m
- Net income in USD162.11m
- Incorporated2006
- Employees124.00
- LocationProtagonist Therapeutics Inc7707 Gateway Blvd Ste 140NEWARK 94560-1160United StatesUSA
- Phone+1 (510) 474-0170
- Fax+1 (302) 636-5454
- Websitehttps://www.protagonist-inc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ligand Pharmaceuticals Inc | 118.31m | 96.34m | 1.53bn | 58.00 | 16.25 | 1.89 | 11.56 | 12.91 | 5.23 | 5.23 | 6.52 | 45.00 | 0.1372 | 0.5475 | 4.11 | 2,039,879.00 | 11.17 | 12.32 | 11.98 | 12.99 | 91.82 | 81.65 | 81.43 | 80.32 | 19.51 | -- | 0.00 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
Avadel Pharmaceuticals PLC (ADR) | 55.14m | -156.83m | 1.53bn | 154.00 | -- | 19.55 | -- | 27.80 | -1.86 | -1.86 | 0.6334 | 0.8157 | 0.3573 | -- | 4.80 | 358,058.40 | -101.63 | -40.21 | -172.85 | -47.99 | 95.71 | -- | -284.42 | -374.75 | 2.60 | -14.71 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
Dynavax Technologies Corp | 236.15m | 9.22m | 1.57bn | 408.00 | 240.04 | 2.54 | 114.76 | 6.65 | 0.05 | 0.05 | 1.67 | 4.73 | 0.2414 | 0.7769 | 3.24 | 578,796.60 | 0.9427 | 4.16 | 1.02 | 5.71 | 80.34 | 64.83 | 3.91 | 9.19 | 14.10 | -- | 0.265 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
Kura Oncology Inc | 0.00 | -168.09m | 1.57bn | 142.00 | -- | 3.11 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
Neumora Therapeutics Inc | 0.00 | -254.02m | 1.58bn | 120.00 | -- | 3.72 | -- | -- | -2.44 | -2.44 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 1.59bn | 111.00 | -- | 3.71 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
Edgewise Therapeutics Inc | 0.00 | -105.85m | 1.60bn | 92.00 | -- | 2.99 | -- | -- | -1.53 | -1.53 | 0.00 | 5.73 | 0.00 | -- | -- | 0.00 | -23.52 | -- | -24.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
Ardelyx Inc | 159.11m | -65.81m | 1.61bn | 267.00 | -- | 10.64 | -- | 10.09 | -0.2883 | -0.2883 | 0.7007 | 0.6449 | 0.5689 | 3.20 | 7.90 | 595,917.60 | -23.53 | -46.14 | -29.95 | -57.32 | 85.30 | 88.15 | -41.36 | -240.87 | 4.36 | -9.86 | 0.3982 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
Taro Pharmaceutical Industries Ltd | 629.18m | 53.87m | 1.61bn | 1.55k | 29.88 | 0.8977 | 18.94 | 2.56 | 1.43 | 1.43 | 16.74 | 47.70 | 0.2928 | 1.50 | 3.31 | -- | 2.51 | -0.166 | 3.03 | -0.2023 | 48.47 | 52.85 | 8.56 | -0.6294 | 3.04 | -- | 0.00 | -- | 9.81 | -1.25 | 111.70 | -28.17 | 12.06 | -- |
Syndax Pharmaceuticals Inc | 0.00 | -240.63m | 1.64bn | 112.00 | -- | 3.33 | -- | -- | -3.22 | -3.22 | 0.00 | 5.79 | 0.00 | -- | -- | 0.00 | -47.99 | -27.90 | -51.84 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
Protagonist Therapeutics Inc | 314.95m | 162.11m | 1.65bn | 124.00 | 11.45 | 2.94 | 10.12 | 5.24 | 2.46 | 2.46 | 5.25 | 9.56 | 0.7248 | -- | 2.10 | 2,812,080.00 | 37.30 | -35.90 | 40.23 | -41.36 | -- | -- | 51.47 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
Sana Biotechnology Inc | 0.00 | -308.61m | 1.66bn | 328.00 | -- | 4.42 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -43.21 | -38.99 | -48.50 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.67bn | 246.00 | 12.69 | 3.24 | 10.30 | 2.70 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
Keros Therapeutics Inc | 234.00k | -160.30m | 1.69bn | 141.00 | -- | 3.72 | -- | 7,227.57 | -5.14 | -5.14 | 0.0075 | 12.59 | 0.0005 | -- | -- | 1,720.59 | -36.84 | -35.95 | -38.35 | -38.07 | -- | -- | -68,505.13 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
Holder | Shares | % Held |
---|---|---|
Farallon Capital Management LLCas of 31 Mar 2024 | 5.74m | 9.85% |
RTW Investments LPas of 31 Mar 2024 | 5.32m | 9.12% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 4.12m | 7.08% |
BVF Partners LPas of 31 Mar 2024 | 3.76m | 6.45% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.27m | 5.62% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 3.07m | 5.27% |
Adage Capital Management LPas of 31 Mar 2024 | 2.22m | 3.81% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.82m | 3.13% |
Cowen & Co. LLCas of 31 Mar 2024 | 1.56m | 2.67% |
Geode Capital Management LLCas of 31 Mar 2024 | 1.29m | 2.22% |